Eexperimental MorphoSys blood cancer drug shows mixed results

The drug hit its primary target but faltered in addressing patient symptoms, raising questions about its prospects for approval.

November 24, 2023 Check out STAT+

Sponsored By

Adobe STAT+ | Mixed study results for MorphoSys blood-cancer drug raise questions about approval Mixed study results for Morphosys blood-cancer drug raise questions about approval By Andrew Joseph and Adam Feuerstein Opinion: Listen: Living in cancer limbo A philosopher who has cancer and his wife, a social medicine expert, discuss diagnostic tests, Stoicism, cancer language, and more. By Torie Bosch STAT+ | Evelo Biosciences, a microbiome company launched by Flagship, shuts down The biotech, which was based in Cambridge, Mass., launched in 2015 and was one of the first companies in the microbiome field. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser